HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer
Year: 2019
Type: preprint
Study design: Clinical Trial
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.3495608
Authors: James Chih-Hsin Yang, D. Ross Camidge, Cheng-Ta Yang, Jianying Zhou, Renhua Guo, Chao-Hua Chiu, Gee-Chen Chang, Her-Shyong Shiah, Yuan Chen, Chin-Chou Wang, David Berz, Wu-Chou Su, Nong Yang, Ziping Wang, Jian Fang, Jianhua Chen, Petros Nikolinakos, You Lu, Hongming Pan, Ajit Maniam, Lyudmila Bazhenova, Keisuke Shirai, Mohammad Jahanzeb, Maurice Willis, Nehal Masood, Naveed Chowhan, Te-Chun Hsia, Hong Jian, Shun Lu
Institutions: National Taiwan University, Chang Gung University, Chang Gung Memorial Hospital, Zhejiang University, Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Taipei Veterans General Hospital, National Yang Ming University, Taichung Veterans General Hospital, Taipei Medical University, Huazhong University of Science and Technology, Linkou Chang Gung Memorial Hospital, Beverly Hills Cancer Center, National Cheng Kung University, Central South University, Peking University Cancer Hospital, Hunan Cancer Hospital, University Cancer and Blood Center, Sichuan University, West China Hospital of Sichuan University, University of California San Diego, Dartmouth College, Dartmouth–Hitchcock Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, The University of Texas Medical Branch at Galveston, MultiCare Health System, China Medical University, China Medical University, Shanghai Jiao Tong University, Shanghai Chest Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3166962960